ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.1
  1. ホーム
  2. /化合物

フレカイニド

Flecainide

HCID 3356
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
54143-55-4
標準SMILES
O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F
InChIKey
DJBNUMBKLMJRSA-UHFFFAOYSA-N
分子式
C17H20F6N2O3
平均分子量
414.34 g/mol
単同位体質量
414.13781148

概要

Flecainide is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart). It has a role as an anti-arrhythmia drug. It is a member of piperidines, a monocarboxylic acid amide, an aromatic ether and an organofluorine compound. It is a conjugate base of a flecainide(1+).

名称と識別子

優先名称
Flecainide
IUPAC
N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
現地名
フレカイニド
英語名
Flecainide
分子式
C17H20F6N2O3
分子量
414.34

名称と別名

flecainide54143-55-4FlecaineN-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideFlecainidaFlecainidum(+-)-FlecainideN-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideCCRIS 313Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-DTXSID8023054NSC-719273
名称をさらに表示
(+)-N-(2-ピペリジニルメチル)-2,5-ビス(2,2,2-トリフルオロエトキシ)ベンズアミドフレカイニド(+)-フレカイニドN-(2-ピペリジニルメチル)-2,5-ビス(2,2,2-トリフルオロエトキシ)ベンズアミドN-(2-ピペリジルメチル)-2,5-ビス(2,2,2-トリフルオロエトキシ)ベンズアミド(-)-N-(2-ピペリジニルメチル)-2,5-ビス(2,2,2-トリフルオロエトキシ)ベンズアミド(-)-フレカイニド2,5-ビス(2,2,2-トリフルオロエトキシ)-N-(ピペリジン-2-イルメチル)ベンズアミドN-(ピペリジン-2-イルメチル)-2,5-ビス(2,2,2-トリフルオロエトキシ)ベンズアミドFlecainide-d4Flecaniderac FlecainideFLECAINTDE BASEFlecainide USP/EP/BP(±)-Flecainide solution(±)-Flecainide solutionN-(Piperidin-2-ylmethyl)

物性

構造計算による物性補完中

XLogP
3.8
極性表面積
59.6 Ų
水素結合供与体数
2
水素結合受容体数
10
回転可能結合数
7
重原子数
28
形式電荷
0
複雑度
500

実験および物理化学的性質

PFASPFAS -> PFAS identified in REACH Regulation EC No. 1272/2008
Drugs · 3 件

Pharmaceuticals

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Cardiovascular system -> Cardiac therapy

LogP · 2 件

4.6

3.78

Solubility3.24e-02 g/L
Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Antiarrhythmics

Pharmaceuticals

Melting Point228-229
Physical DescriptionSolid
Dissociation Constants · 2 件

9.3

9.3

Collision Cross Section192.2 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

物理化学的性質

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P270, P271, P280, P301+P317, P304+P340, P318, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationREACH registered substance: N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide (EC: 685-650-9)
Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Treatment · 1 件

Treatment of flecainide toxicity involves increasing the excretion of flecainide, blocking its effects in the heart, and (rarely) institution of cardiovascular support to avoid impending lethal arrhythmias. Modalities that have had success include administration of a beta-sympathomimetic agent, and administration of a sodium load (often in the form of hypertonic sodium bicarbonate). Placing the individual on cardiopulmonary bypass support may be necessary in order to temporarily obviate the need for a beating heart and to increase blood flow to the liver. (L1129)

Health Effects · 1 件

Signs of flecainide toxicity include marked prolongation of the PR interval and widening of the QRS duration on the surface ECG. There may be signs and symptoms attributable to overt heart failure secondary to sudden decreased myocardial contractility (L1129).

Hepatotoxicity · 1 件

In clinical trials, flecainide was associated with a low rate of serum aminotransferase and alkaline phosphatase elevations. Despite wide scale use, flecainide has only rarely been linked to cases of clinically apparent liver injury. The typical presentation is with a cholestatic hepatitis arising within 1 to 6 weeks of starting flecainide. In addition, instances of acute hepatic injury arising within 1 to 3 days of starting flecainide with marked, but short lived elevations in serum aminotransferase levels and minimal increases in alkaline phosphatase have been published, but may actually represent acute worsening of congestive heart failure and ischemic hepatitis due to the proarrhythmic effects of flecainide. In all instances, the liver injury was self limited. Immunoallergic and autoimmune features were not present.

化学と産業

薬理情報

ATC Code · 3 件

C01BC04

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingFlecainide is 40% bound to protein in serum, mainly to alpha-1-acid glycoprotein and minorly to serum albumin.
Pharmacodynamics · 1 件

Flecainide inhibits the action of sodium and potassium ion channels in the heart, raising the threshold for depolarization and correcting arrhythmias. Flecainide has a long duration of action, allowing for once daily dosing. The therapeutic index is narrow. Patients should not take this medication if there is already structural heart disease or left ventricular systolic dysfunction.

Mechanism of Action · 1 件

Flecainide blocks fast inward sodium channels and slowly unbinds during diastole, prolonging the refractory period of the heart. This blockade also shortens the duration of action potentials through the Purkinjie fibers. Flecainide also prevents delayed rectifier potassium channels from opening, lengthening the action potential through ventricular and atrial muscle fibers. Finally, flecainide also blocks ryanodine receptor opening, reducing calcium release from sarcoplasmic reticulum, which reduces depolarization of cells.

Biological Half-Life · 1 件

In healthy subjects, intravenous flecainide has an average half life of 13 hours for a single dose and 16 hours for multiple oral doses. In patients with a ventricular premature complex, flecainide has a half life of 20 hours. The half life of meta-O-dealkylated flecainide, a major metabolite of flecainide, is 12.6h.

Metabolism/Metabolites · 2 件

Flecainide is mainly metabolized to meta-O-dealkylated flecainide or the meta-O-dealkylated lactam of flecainide. Meta-O-dealkylated flecainide has 20% the activity of flecainide. Both of these metabolites are generally detected as glucuronide or sulfate conjugates. Flecainide’s metabolism involves the action of CYP2D6 and CYP1A2.

Hepatic. Flecainide does not undergo any consequential presystemic biotransformation. The two major urinary metabolites are meta-O-dealkylated flecainide (active, but about one-fifth as potent) and the meta-O-dealkylated lactam of flecainide (non-active metabolite). The absoprtion is nearly complete following oral administration. Hepatic. Flecainide does not undergo any consequential presystemic biotransformation. The two major urinary metabolites are meta-O-dealkylated flecainide (active, but about one-fifth as potent) and the meta-O-dealkylated lactam of flecainide (non-active metabolite). Route of Elimination: In healthy subjects, about 30% of a single oral dose (range, 10 to 50%) is excreted in urine as unchanged drug. Several minor metabolites (3% of the dose or less) are also found in urine; only 5% of an oral dose is excreted in feces. In patients, free (unconjugated) plasma levels of the two major metabolites are very low (less than 0.05 ug/mL). Half Life: 20 hours (range 12-27 hours)

関連反応

14 件
反応記録を作成
HRID 460428 の反応式
HRID 460428生成物としてuspto-grants-2007_03
HRID 460429 の反応式
HRID 460429反応物としてuspto-grants-2007_03
HRID 838420 の反応式
HRID 838420生成物としてTest data from https://doi.org/10.1039/C8SC04228D
HRID 959705 の反応式
HRID 959705反応物としてValidation data from https://doi.org/10.1039/C8SC04228D
HRID 1138736 の反応式
HRID 1138736反応物としてTraining data from https://doi.org/10.1039/C8SC04228D (7/10)
HRID 1359120 の反応式
HRID 1359120反応物としてuspto-grants-2003_07
HRID 1359121 の反応式
HRID 1359121生成物としてuspto-grants-2003_07
HRID 2290621 の反応式
HRID 2290621反応物としてuspto-grants-1986_10
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
K94FTS1806DTXCID403054CHEBI:75984THN-102 COMPONENT FLECAINIDEFlecainid IsisRefChem:56566C01BC04685-650-9

データベース識別子

CAS
54143-55-4、54143-56-5
PubChem CID
3356
DTXSID
DTXSID8023054
ChEMBL
CHEMBL652
ChEBI
CHEBI:75984
UNII
K94FTS1806
EC Number
685-650-9、923-247-4
Nikkaji
J12.413C、J399.064H、J399.065F
融点
105 · 105-1070C
沸点
434.9 · 434.9±45.0 °C(Predicted)
比重(密度)
1.286 · 1.286±0.06 g/cm3(Predicted)
闪点
9 ℃ · 9℃
貯蔵温度
Keep in dark place,Inert atmosphere,Room temperature
溶解性
クロロホルム(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
9.3 · pKa 9.3 (Uncertain)
色
ホワイトからオフホワイト
BCS Class
1 or · 1 or 2
主な用途
臨床検査
InChI
1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)
InChIKey
DJBNUMBKLMJRSA-UHFFFAOYSA-N
SMILES
O=C(NCC1CCCCN1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F
CAS データベース
54143 · 54143-55-4(CAS DataBase Reference)
NISTの化学物質情報
2 · Benzamide, n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-(54143-55-4)

化学的性質

化学的特性White Crystalline Powder

Adverse EffectsCardiac Toxicity
Exposure RoutesIngestion (MSDS, A308). Nearly complete following oral administration.
Toxicity Summary · 2 件

Signs and Symptoms of Overdose

Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.

Signs and Symptoms · 1 件

Symptoms of overdose include nausea and vomiting, convulsions, hypotension, bradycardia, syncope, extreme widening of the QRS complex, widening of the QT interval, widening of the PR interval, ventricular tachycardia, AV nodal block, asystole, bundle branch block, cardiac failure, and cardiac arrest.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

flecainide

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 50-498 mg/kg (Oral, Rat) (A308)

安全データ

wgk
1
ridadr
3249
risk_code
11-23/24/25-39/23/24/25
hazard_code
F,T
safety_code
7-16-36/37-45
hazard_class
6.1(b)
packing_group
III
Hazard Classifications
Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1
ストレージクラス
3 - Flammable liquids
FDA Pharmacological Classification · 4 件

K94FTS1806

FLECAINIDE

Established Pharmacologic Class [EPC] - Antiarrhythmic

Flecainide is an Antiarrhythmic.

MeSH Pharmacological Classification · 2 件

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.

Absorption, Distribution and Excretion · 4 件

Oral flecainide has a Tmax of 3-4h and a bioavialability of 90%. Taking flecainide with food or aluminum hydroxide antacids do not significantly affect the absorption of flecainide.

Approximately 86% of a single oral dose is eliminated in the urine, with 42% as unchanged flecainide and 14% as meta-O-dealkylated flecainide, a similar amount of the meta-O-dealkylated lactam of flecainide, approximately 3% as an unidentified acid metabolite, and <1% as 2 other unknown metabolites. 5% is eliminated in the feces.

The average volume of distribution in 8 male subjects is 5.0-13.4L/kg.

The average clearance of intravenous flecainide is 4.6-12.1mL/min/kg in 8 male subjects. For oral flecainide, the clearance was 4-20mL/min/kg.

Cellular LocationsMembrane
Metabolite PathwaysFlecainide Action Pathway

用途と製造

Uses · 2 件

Use (kg; approx.) in Germany (2009): >2500

Flecainide is is a class Ic antiarrhythmic agent and as such, it is used for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disablin (A308).

Use ClassificationPharmaceuticals

応用分野

説明From the chemical point, flecainide is an analog of procainamide, to which a 2.2.2-trifluoroethoxyl group was added at C2 and C3 of the benzene ring, and a diaminoethyl side chain is ended in the piperidine ring.

使用Flecainide, as with other local anesthetics, is used for naturally occurring ventricular arrhythmia.

上流・下流製品情報

上流原料

ピペリジン-2-メタンアミンDesiccantゲンチシン酸2-ピコリルアミン硫酸マグネシウム (無水)塩酸2,5-ビス(2,2,2-トリフルオロエトキシ)安息香酸2,5-ビス(2,2,2-トリフルオロエトキシ)安息香酸2,2,2-トリフルオロエチル2,5-ビス(2,2,2-トリフルオロエトキシ)安息香酸メチル
補足説明 · 1 件

定義ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prev nt and treat tachyarrhythmia (abnormal fast rhythm of the heart).